<p>
    Imaging Surveillance:
</p>
<ul>
    <li data-list-item-id="e536002225d0d377323a80c0d7c2b90b4">
         HCC (RETREAT score based)
        <ul>
            <li data-list-item-id="e16b84938a3cde37593c6da42fbf76de2">
                 Score 0–3: CT chest/abdomen + AFP q6 months × 2 yrs
            </li>
            <li data-list-item-id="e21fc779314325fb269b57bd68e00853e">
                 Score 4: Same × 5 yrs + consider sirolimus/minimize IS
            </li>
            <li data-list-item-id="e8c5caf78dac432c5f113c68b77ea0c8a">
                 Score ≥5: CT/AFP q3 months × 2 yrs → q6 months × 2–5 yrs + consider sirolimus/minimize IS
            </li>
        </ul>
    </li>
    <li data-list-item-id="e42fdda7ed165302ba8fe658492eb6bc6">
         Cholangiocarcinoma:
        <ul>
            <li data-list-item-id="e161da3778e91835aaa6bd6512381839c">
                 Mayo protocol: MRI abd + CT chest + CA19-9 q3–6 months lifelong.
            </li>
            <li data-list-item-id="e43e566f84c534b2cf1addb59dd297fc7">
                 Incidental: MRI abd + CT chest + CA19-9 q3 months × 2 yrs → q6 months × 3 yrs → annually lifelong
            </li>
        </ul>
    </li>
    <li data-list-item-id="e20c075f4adc8605f79f3099ca81fbe0b">
         PSC: MRCP q2–3 yrs.
    </li>
    <li data-list-item-id="e5cdecc8266c9c326c8353fd744bebdca">
         Fibroscan: All patients: q1–2 yrs.&nbsp;
    </li>
</ul>